Combination of Phosphorylated and Truncated EGFR Correlates With Higher Tumor and Nodal Stage in Head and Neck Cancer

REFERENCES

• Kolibaba, K.S.; Druker, B.J. Protein tyrosine kinases and cancer. Biochim Biophys Acta 1997 Dec 9, 1333(3), F217–F248.
   PubMed Web of Science ®Google Scholar
• Rubin Grandis, J.; Melhem, M.F.; Gooding, W.E.; Day, R.; Holst, V.A.; Wagener, M.M.; Drenning, S.D.; Tweardy, D.J. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998 Jun 3, 90(11), 824–832.
   PubMed Web of Science ®Google Scholar
• Ang, K.K.; Berkey, B.A.; Tu, X.; Zhang, H.Z.; Katz, R.; Hammond, E.H.; Fu, K.K.; Milas, L. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002 Dec 15, 62(24), 7350–7356.
   PubMed Web of Science ®Google Scholar
• Kong, A.; Leboucher, P.; Leek, R.; Calleja, V.; Winter, S.; Harris, A.; Parker, P.J.; Larijani, B. Prognostic value of an activation state marker for epidermal growth factor receptor in tissue microarrays of head and neck cancer. Cancer Res 2006 Mar 1, 66(5), 2834–2843.
   PubMed Web of Science ®Google Scholar
• Hiraishi, Y.; Wada, T.; Nakatani, K.; Negoro, K.; Fujita, S. Immunohistochemical expression of EGFR and p-EGFR in oral squamous cell carcinomas. Pathol Oncol Res 2006, 12(2), 87–91.
   PubMed Web of Science ®Google Scholar
• Sok, J.C.; Coppelli, F.M.; Thomas, S.M.; Lango, M.N.; Xi, S.; Hunt, J.L.; Freilino, M.L.; Graner, M.W.; Wikstrand, C.J.; Bigner, D.D.; Gooding, W.E.; Furnari, F.B.; Grandis, J.R. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006 Sep 1, 12(17), 5064–5073.
   PubMed Web of Science ®Google Scholar
• Slamon, D.J.; Godolphin, W.; Jones, L.A.; Holt, J.A.; Wong, S.G.; Keith, D.E.; Levin, W.J.; Stuart, S.G.; Udove, J.; Ullrich, A.; Press, M.F. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989 May 12, 244(4905), 707–712.
   PubMed Web of Science ®Google Scholar
• Agazie, Y.M.; Hayman, M.J. Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling. Mol Cell Biol 2003 Nov, 23(21), 7875–7886.
   PubMed Web of Science ®Google Scholar
• Bode, B.; Frigerio, S.; Behnke, S.; Senn, B.; Odermatt, B.; Zimmermann, D.R.; Moch, H. Mutations in the tyrosine kinase domain of the EGFR gene are rare in synovial sarcoma. Mod Pathol 2006 Apr, 19(4), 541–547.
   PubMed Web of Science ®Google Scholar
• Hama, T.; Yuza, Y.; Saito, Y.; Ou, J.; Kondo, S.; Okabe, M.; Yamada, H.; Kato, T.; Moriyama, H.; Kurihara, S.; Urashima, M. Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma. Oncologist 2009 Sep, 14(9), 900–908.
   PubMed Web of Science ®Google Scholar
• Quon, H.; Liu, F.F.; Cummings, B.J. Potential molecular prognostic markers in head and neck squamous cell carcinomas. Head Neck 2001 Feb, 23(2), 147–159.
   PubMed Web of Science ®Google Scholar
• Ford, A.C.; Grandis, J.R. Targeting epidermal growth factor receptor in head and neck cancer. Head Neck 2003 Jan, 25(1), 67–73.
   PubMed Web of Science ®Google Scholar
• Etienne, M.C.; Pivot, X.; Formento, J.L.; Bensadoun, R.J.; Formento, P.; Dassonville, O.; Francoual, M.; Poissonnet, G.; Fontana, X.; Schneider, M.; Demard, F.; Milano, G. A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil. Br J Cancer 1999 Apr, 79(11–12), 1864–1869.
   PubMed Web of Science ®Google Scholar
• Cohen, E.E.; Rosen, F.; Stadler, W.M.; Recant, W.; Stenson, K.; Huo, D.; Vokes, D.E. Phase-II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003 May 15, 21(10), 1980–1987.
   PubMed Web of Science ®Google Scholar
• Soulieres, D.; Senzer, N.N.; Vokes, E.E.; Hidalgo, M.; Agarwala, S.S.; Siu, L.L. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004 Jan 1, 22(1), 77–85.
   PubMed Web of Science ®Google Scholar
• Baselga, J.; Trigo, J.M.; Bourhis, J.; Tortochaux, J.; Cortes-Funes, H.; Hitt, R.; Gascon, P.; Amellal, N.; Harstrick, A.; Eckhardt, A. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005 Aug 20, 23(24), 5568–5577.
   PubMed Web of Science ®Google Scholar
• Bonner, J.A.; Harari, P.M.; Giralt, J.; Azarnia, N.; Shin, D.M.; Cohen, R.B.; Jones, C.U.; Sur, R.; Raben, D.; Jassem, J.; Ove, R.; Kies, M.S.; Baselga, J.; Youssoufian, H.; Amellal, N.; Rowinsky, E.K.; Ang, K.K. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006 Feb 9, 354(6), 567–578.
   PubMed Web of Science ®Google Scholar
• Pedersen, M.W.; Meltorn, M.; Damstrup, L.; Poulsen, H.S. The type-III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Ann Oncol 2001 Jun, 12(6), 745–760.
   PubMed Web of Science ®Google Scholar
• Ji, H.; Zhao, X.; Yuza, Y.; Shimamura, T.; Li, D.; Protopopov, A.; Jung, B.L.; McNamara, K.; Xia, H.; Glatt, K.A.; Thomas, R.K.; Sasaki, H.; Horner, J.W.; Eck, M.; Mitchell, A.; Sun, Y.; Al-Hashem, R.; Bronson, R.T.; Rabindran, S.K.; Discafani, C.M.; Maher, E.; Shapiro, G.I.; Meyerson, M.; Wong, K.K. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci USA 2006 May 16, 103(20), 7817–7822.
   PubMed Web of Science ®Google Scholar
• Frederick, L.; Wang, X.Y.; Eley, G.; James, C.D. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 2000 Mar 1, 60(5), 1383–1387.
   PubMed Web of Science ®Google Scholar
• Frederick, L.; Eley, G.; Wang, X.Y.; James, C.D. Analysis of genomic rearrangements associated with EGRFvIII expression suggests involvement of Alu repeat elements. Neuro Oncol 2000 Jul, 2(3), 159–163.
   PubMed Web of Science ®Google Scholar
• Loeffler-Ragg, J.; Witsch-Baumgartner, M.; Tzankov, A.; Hilbe, W.; Schwentner, I.; Sprinzl, G.M.; Utermann, G.; Zwierzina, H. Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. Eur J Cancer 2006 Jan, 42(1), 109–111.
   PubMed Web of Science ®Google Scholar
• Lee, J.W.; Soung, Y.H.; Kim, S.Y.; Nam, H.K.; Park, W.S.; Nam, S.W.; Kim, M.S.; Sun, D.I.; Lee, Y.S.; Jang, J.J.; Lee, J.Y.; Yoo, N.J.; Lee, S.H. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res 2005 Apr 15, 11(8), 2879–2882.
   PubMed Web of Science ®Google Scholar
• Lynch, T.J.; Bell, D.W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R.A.; Brannigan, B.W.; Harris, P.L.; Haserlat, S.M.; Supko, J.G.; Haluska, F.G.; Louis, D.N.; Christiani, D.C.; Settleman, J.; Haber, D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004 May 20, 350(21), 2129–2139.
   PubMed Web of Science ®Google Scholar